A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.
The present invention relates to a binding agent capable of specifically binding to and inhibiting competitively a neutrophil elastase, which binding agent comprises an immunoglobulin single variable domain (ISVD), as well as related products, methods, and uses, such as in particular methods and uses aimed at the prevention, treatment, or diagnostics of inflammatory diseases.
A composition including one or more bacteria selected from the genus Parabacteroides and/or an extract thereof and/or metabolites thereof. Also, the use of this composition in methods of preventing and/or treating reward dysregulation disorders, including mental disorders, neurological disorders, and combinations thereof, by administering this composition to an individual in need thereof.
In an ionizing particle detection module, an ionizing particle traversing an ionization chamber produces a local ionization in an ionizable medium within the ionization chamber. A matrix of detection pads face the ionization chamber so that respective detection pads cover respective zones in the ionization chamber. Respective detection channels comprise respective mutually exclusive groups of detection pads. A detection channel provides an indication of a local ionization occurring somewhere within the respective zones in the ionization chamber covered by the respective detection pads of the detection channel. A cluster of detection pads is identified among the detection pads belonging to detection channels simultaneously providing indications of local ionization. A traversing point indication is provided on the basis of the cluster that has been identified if the cluster comprises a predefined minimum number of detection pads. The traversing point indication indicating where the ionizing particle has traversed the ionization chamber.
An electric machine comprises a rotor from which a magnetic field emanates and a stator that produces a magnetic field that interacts with the magnetic field emanating from the rotor. The stator comprising a pair of windings symmetrically positioned with respect to the rotor. A displacement of the rotor causes an increase in magnitude of a magnetic flux induced by the rotor in one winding of the pair of windings and a decrease in magnitude of a magnetic flux induced by the rotor in the other winding of the pair of windings. A driver can make the electric machine operate in an active electromagnetic bearing mode and in a passive electromagnetic bearing mode. In the active electromagnetic bearing mode, the driver applies a suspension signal component to at least one winding of the pair of windings. This causes the magnetic field produced by the stator to have a component that exerts a suspension force on the rotor through interaction with the magnetic field emanating from the rotor. In the passive electromagnetic bearing mode, the driver interconnects the pair of windings of the stator with each other so that the increase in magnitude of the magnetic flux in the one winding and the decrease in magnitude in the other winding of the pair of windings generates a suspension current in the pair of windings. The suspension current causes the magnetic field produced by the stator to have a component that exerts a restoring force on the rotor counteracting the displacement.
The current invention relates to a population comprising human allogenic liver-derived progenitor cells (HALPC), lysates thereof and/or conditioned medium obtainable by culturing said HALPC, for use in the prevention and/or treatment of a patient at risk of or suffering from hepatocellular carcinoma (HCC). The invention also relates to a pharmaceutical composition for use in the prevention and/or treatment of a patient at risk of or suffering from HCC; to a method for the prevention and/or the treatment of a patient at risk of or suffering from HCC; and to a method for reducing HCC growth rate in a patient suffering from HCC.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
7.
METHOD FOR PRODUCING PLASMID DNA USING ESCHERICHIA COLI
Plasmid DNA can be efficiently recovered from bacterial cells when producing plasmid DNA using E. coli. Provided is a method for producing plasmid DNA including the following steps (a) to (c): (a) a step of preparing E. coli, which has a mutation in a gene region associated with maintaining outer membrane properties and has a desired plasmid; (b) a step of culturing E. coli of (a); and (c) a step of recovering a desired plasmid from bacterial cells after culture.
A film (100) is applied as an intermediate between two parts to be joined in a liquid composite molding process, whereby at least one of the two parts comprises a fiber structure. The film (100) has two main surfaces one of which is adapted to contact one of the two parts to be joined, the other main surface being adapted to contact the other one of the two part to be joined. The film (100) comprises a plurality of cavities. An orthographic projection (301-306) of the cavities onto one (101) of the two main surfaces as a projection plane, occupies at least 5 % of this main surface (101).
B29C 65/48 - Assemblage d'éléments préformésAppareils à cet effet en utilisant des adhésifs
B29C 70/48 - Façonnage ou imprégnation par compression pour la fabrication d'objets de longueur définie, c.-à-d. d'objets distincts utilisant des moules opposables, p. ex. pour déformer des préimprégnés [SMC] ou des "prepregs" avec une imprégnation des renforcements dans le moule fermé, p. ex. moulage par transfert de résine [RTM]
B29C 70/08 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement comprenant des combinaisons de différentes formes de renforcements fibreux incorporés dans une matrice, formant une ou plusieurs couches, avec ou sans couches non renforcées
B32B 7/12 - Liaison entre couches utilisant des adhésifs interposés ou des matériaux interposés ayant des propriétés adhésives
C09J 7/10 - Adhésifs sous forme de films ou de pellicules sans support
C09J 11/00 - Caractéristiques des adhésifs non prévues dans le groupe , p. ex. additifs
B29C 70/54 - Parties constitutives, détails ou accessoiresOpérations auxiliaires
B33Y 80/00 - Produits obtenus par fabrication additive
C09J 5/06 - Procédés de collage en généralProcédés de collage non prévus ailleurs, p. ex. relatifs aux amorces comprenant un chauffage de l'adhésif appliqué
9.
SYSTEM AND METHOD FOR DETERMINING A RISK OF HAVING OR DEVELOPING STEATOHEPATITIS AND/OR A COMPLICATION THEREOF
A computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject. The method includes the steps of: receiving at least one image of the subject and at least one clinical and/or biological data, both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image based on at least one radiomic feature obtained for a region of interest including at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject; determining a risk for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
In a modulated metasurface antenna, a surface wave transducer generates a surface wave when a radio-frequency excitation signal is applied to the surface wave transducer. The surface wave propagates throughout a surface wave propagation medium from the surface wave transducer to a rim of the surface wave propagation medium. The surface wave propagation medium has an electromagnetic surface impedance distribution that exhibits impedance variations that extend from the surface wave transducer to the rim of the surface wave propagation medium. The electromagnetic surface impedance distribution is non-uniform in azimuth direction on the surface wave propagation medium. The surface wave transducer has a non-uniform azimuthal surface wave power distribution so that, compared to a uniform azimuthal surface wave power distribution, a smaller amount of surface wave power is launched in the azimuth ranges where the impedance variations are the smallest.
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p. ex. dispositifs quasi optiques
H01Q 3/26 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la phase relative ou l’amplitude relative et l’énergie d’excitation entre plusieurs éléments rayonnants actifsDispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante
H01Q 13/28 - Antennes constituées par un guide non résonnant à ondes de fuite ou une ligne de transmissionStructures équivalentes produisant un rayonnement le long du trajet de l'onde guidée comportant des éléments présentant des discontinuités électriques et espacées dans la direction de la propagation de l'onde, p. ex. élément diélectrique ou élément conducteur formant diélectrique artificiel
11.
TITANIUM ALLOY, POWDER OF THE TITANIUM ALLOY AND METHOD OF MANUFACTURING THEREOF
The present invention relates to the field of metallurgy, more particularly non-ferrous alloys. The first aspect of the present invention relates in particular to titanium (Ti) alloys suitable to be manufactured by a method of additive manufacturing such as laser powder bed fusion. The titanium alloy, according to the present invention, comprises titanium and further metallic elements homogenously dispersed in the titanium alloy matrix, wherein titanium forms a microstructural titanium alloy matrix. The alloy microstructure, when the alloy is subjected to mechanical loading, changes its microstructure from an initial non-deformed state to a final deformed state through a martensitic transformation or a mechanical twinning. The alloy comprises a plurality of defects and a plurality of porosities, wherein the plurality of defects and said plurality of porosities represent between 0,5% and 6% in volume of the alloy.
A polypeptide including the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity of the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. Also, the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
The present invention relates to a method for detecting CALR mutant positive cells in a subject comprising detecting Transferrin Receptor Protein 1 (TFRC) surface levels. The present invention further relates to methods for sorting out CALR mutant cells from health cells, and to methods for treating CALR mutant positive MPNs.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
The present invention relates to a population of cells overexpressing the cytochrome c oxidase subunit VIIb (COX7B) protein, for use in treating and/or preventing a brain disease or disorder in a subject in need thereof, and pharmaceutical compositions or kits comprising the same. The present invention further relates to a method for inducing the brain tropism of cells, preferably stem cells, by using the overexpression of COX7B.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Lactam or lactone derivatives of formula Ia:
Lactam or lactone derivatives of formula Ia:
Lactam or lactone derivatives of formula Ia:
or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is NH or O; X2 is —OH, —O-alkyl, —NH2, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z1 is S, SO, SO2, O, CR3 or NR4; and R1, R2, R3 and R4 each independently are H, alkyl or aryl. Also, the use of lactam or lactone derivatives of formula Ia in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV-2.
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61P 31/14 - Antiviraux pour le traitement des virus ARN
17.
CONTINUOUS PROCESS AND SYSTEM FOR THE PRODUCTION OF SODIUM BICARBONATE CRYSTALS
A continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream including an absorption step of the carbon dioxide from a gas stream into an aqueous solution including a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. A system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream including a control unit, an absorption unit and a crystallization unit.
C01D 7/10 - Préparation de bicarbonates à partir de carbonates
C30B 7/04 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par évaporation du solvant en utilisant des solvants aqueux
18.
RF SUBSTRATE COMPRISING DEPLETION REGIONS INDUCED BY FIELD EFFECT
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgique)
Inventeur(s)
Hutin, Louis
Moulin, Maxime
Fache, Thibaud
Plantier, Christophe
Raskin, Jean-Pierre
Rack, Martin
Abrégé
A structure for an RF device provided with a semiconductor region coated with a heterogeneous dielectric region, the heterogeneous dielectric region including, in at least one first direction parallel to a main plane of the substrate, an alternation of first areas made of a first dielectric material with positive fixed charges and of second dielectric areas made of a second dielectric material with negative fixed charge in order to create an alternation of polarity allowing preventing the formation of a parasitic conduction layer in the semiconductor region.
The present invention relates to an optical lens for augmented visual perception of a scene, the optical lens comprising a bandpass filter or a blurring filter, so as to lower contrast and high spatial frequencies of the scene.
G02C 7/10 - Filtres, p. ex. pour faciliter l'adaptation des yeux à l'obscuritéLunettes de soleil
20.
PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION
A parapharmaceutical or pharmaceutical composition is administrable to living beings, and in particular to human beings. The composition includes at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml. The composition is for curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.
A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.
Genetically modified gram-negative bacteria, in particular E. coli, that are oversensitive to lysis. These bacteria are therefore useful to improve the yield of nucleic acid extraction, preferably extra-genomic nucleic acid extraction (e.g. plasmid), and/or the yield of a polypeptide, preferably encoded by an extra-genomic nucleic acid. In practice, the strains of E. coli are engineered with a combination of at least 2 mutated genes altering the envelop integrity. More particularly, at least one mutated gene is ompA and at least one mutated gene is a gene involved in Lpp functionality, such as, e.g., the lpp gene, the ybiS gene, the ycfS gene and the erfK gene. These combinations also include mutations in genes that are homologue to the ompA gene, and/or the lpp gene.
The present invention relates to a polypeptide comprising fragments of the extracellular domain of thrombopoietin receptor, a fusion protein and a pharmaceutical composition comprising said polypeptide, and uses thereof.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
24.
SOLUBLE THROMBOPOIETIN RECEPTOR FRAGMENTS AND USES THEREOF
The present invention relates to a polypeptide comprising the extracellular domain of the thrombopoietin receptor or fragments thereof, and its use as a medicament. The present invention also relates to the treatment and/or prevention of thrombopoietin-related diseases, in particular myeloproliferative neoplasms.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
The present invention relates to a population of human allogenic liver-derived progenitor cells (HALPC), lysates thereof and/or conditioned medium obtainable by culturing said HALPC, for treating and/or preventing cellular senescence in a subject in need thereof. The treatment and/or prevention of cellular senescence using the cell population of the invention, a lysate thereof and/or a conditioned medium obtainable by its culture, has a positive effect on other diseases, in particular diseases associated with cellular senescence.
The present invention relates to a device for heart valve repair configured to be implanted around a heart valve of a subject, the heart valve comprising an annulus and at least two leaflets, the device comprising: a base configured to fit around the annulus of the heart valve, so as to limit a radially outward displacement of said annulus; at least two elongated members extending from the base, each elongated member extending parallel to a longitudinal axis and ending in a free top opposite to the base and being sized to extend between the annulus of the heart valve and a commissure between the at least two leaflets; a securing member configured to join at least two free tops, so as to limit an outward displacement of said free tops when the device is implanted around the heart valve.
The present invention relates to antibodies capable of activating TGF-β1, in particular antibodies that can bind to latent TGF-β1 and release the mature TGF-β1 cytokine, and uses thereof.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C07K 14/495 - Facteur de croissance transformant [TGF]
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to bispecific antibodies or antibody fragments thereof comprising an antigen binding region that binds to latent TGF-β1 and an antigen binding region that binds to GARP, and uses thereof.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C07K 14/495 - Facteur de croissance transformant [TGF]
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
29.
METHODS AND COMPOSITIONS FOR INCREASING STRESS TOLERANCE OF CELLS AND ORGANISMS
The present application provides an in vitro method for increasing tolerance of a cell to a stress factor, such as radiation, wherein said method comprises genetically engineering the cell to express a specific DNA ligase or a biologically active fragment thereof. Also genetically engineered cells that express the specific DNA ligase or a biologically active fragment thereof are provided, as well as recombinant polynucleotides comprising a polynucleotide that encodes the specific DNA ligase or a biologically active fragment thereof. Further, the genetically engineered cells are provided for use as a medicament or in a pharmaceutical composition. Finally, also method of using the genetically engineered cells in an environment characterized by radiation that is higher than terrestrial background is provided.
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following operations in an iterative manner. Measurements carried out by the follower aircraft are estimated based on a simulated response of the follower aircraft to an estimated aerodynamic context. The estimated aerodynamic context includes a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context is adjusted based on a comparison between the measurements that have been estimated and actual measurements carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information on the wake is extracted from the estimated aerodynamic context.
In an energy harvesting system, a power extraction circuit extracts electrical power from an environmental power source susceptible of providing a level of power that fluctuates. An electrical power storage device stores the electrical power extracted from the environmental power source by the power extraction circuit. A sensing circuit provides an indication of a level of power that the power extraction circuit can extract from the environmental power source. A controlled switch circuit electrically decouples the power extraction circuit from the electrical power storage device when the indication indicates that the level of power that the power extraction circuit can extract from the environmental power source is insufficient for the power extraction circuit to charge the electrical power storage device. This prevents leakage of harvested power.
H02J 50/00 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique
H02J 50/20 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant des micro-ondes ou des ondes radio fréquence
33.
ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
34.
ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS
The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.
In an ionizing particle detection module (100), an ionizing particle traversing an ionization chamber (103) produces a local ionization in an ionizable medium within the ionization chamber (103). A matrix of detection pads (104) face the ionization chamber (103) so that respective detection pads cover respective zones in the ionization chamber (103). Respective detection channels (105) comprise respective mutually exclusive groups of detection pads according to the following rules. Firstly, the detection pads of a detection channel are nonadjacent and dispersed throughout the matrix. Secondly, two detection channels have a maximum of two detection pads next to each other in the matrix, one of the two detection pads belonging to one of the two detection channels, the other of the two detection pads belonging to the other of the two detection channels. A detection channel (107) provides an indication of a local ionization occurring somewhere within the respective zones in the ionization chamber (103) covered by the respective detection pads of the detection channel (107). A cluster of detection pads is identified among the detection pads belonging to detection channels simultaneously providing indications of local ionization. A traversing point indication is provided (102) on the basis of the cluster that has been identified if the cluster comprises a predefined minimum number of detection pads. The traversing point indication indicating where the ionizing particle has traversed the ionization chamber (103).
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According to one embodiment, each acetylated-sialic acid is independently selected from 4-O-acetylated-sialic acid, 7-O-acetylated-sialic acid, 8-O-acetylated-sialic acid and 9-O-acetylated-sialic acid. This invention also relates to a glycocluster for use in the treatment and/or prevention of an infectious disease, such as a coronavirus infection.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
C07H 23/00 - Composés contenant du bore, du silicium ou un métal, p. ex. chélates ou vitamine B12
A61P 31/14 - Antiviraux pour le traitement des virus ARN
37.
ACETYLATED SIALIC ACID GLYCOCLUSTERS AND THEIR USES FOR TREATING INFECTIOUS DISEASES
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According to one embodiment, each acetylated-sialic acid is independently selected from 4-O-acetylated-sialic acid, 7-O-acetylated-sialic acid, 8-O-acetylated-sialic acid and 9-O-acetylated-sialic acid. This invention also relates to a glycocluster for use in the treatment and/or prevention of an infectious disease, such as a coronavirus infection.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
NATIONAL UNIVERSITY CORPORATION KYUSHU UNIVERSITY (Japon)
UNIVERSITÉ CATHOLIQUE DE LOUVAIN (Belgique)
Inventeur(s)
Kin, Tadahiro
Cortina Gil, Eduardo
Giammanco, Andrea
Abrégé
Providing a magnetic field structure imaging apparatus capable of easily obtaining a magnetic field structure image of a target region. A magnetic field structure imaging apparatus comprising: a first detection unit that detects a passing position of a muon having passed through a target region; a second detection unit that detects a passing position of the muon having passed through the target region and the first detection unit; an analysis unit that calculates a magnetic field structure image of the target region on the basis of an arrival trajectory of the muon detected by the first detection unit and the second detection unit; and a display unit that displays at least one of the magnetic field structure image and magnitude and/or direction of two-dimensional magnetic flux density calculated from the magnetic field structure image, wherein a cosmic ray muon is used as the muon; and magnetic field structure imaging method.
G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
39.
PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
The present invention relates to a composition comprising one or more bacteria from the genus Parabacteroides and/or an extract thereof, for use in preventing and/or treating reward dysregulation disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
41.
PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS
The present invention relates to a composition comprising one or more bacteria from the genus Parabacteroides and/or an extract thereof, for use in preventing and/or treating reward dysregulation disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
The purpose of the present invention is to collect plasmid DNA from a cell body of Escherichia coli with high efficiency in the production of the plasmid DNA using the Escherichia coli. Provided is a method for producing plasmid DNA, the method comprising the following steps (a) to (c): (a) preparing Escherichia coli that has a mutation in a gene region involved in the retention of the properties of an outer membrane thereof and carries a desired plasmid; (b) culturing the Escherichia coli prepared in the step (a); and (c) collecting the desired plasmid from the cultured cells.
An electric machine (300) comprises a rotor (303) from which a magnetic field emanates and a stator that produces a magnetic field that interacts with the magnetic field emanating from the rotor. The stator comprising a pair of windings (304, 305) symmetrically positioned with respect to the rotor (303). A displacement of the rotor (303) causes an increase in magnitude of a magnetic flux induced by the rotor (303) in one winding of the pair of windings (304, 305) and a decrease in magnitude of a magnetic flux induced by the rotor (303) in the other winding of the pair of windings (304, 305). A driver (301) can make the electric machine operate in an active electromagnetic bearing mode and in a passive electromagnetic bearing mode. In the active electromagnetic bearing mode, the driver (301) applies a suspension signal component to at least one winding of the pair of windings. This causes the magnetic field produced by the stator to have a component that exerts a suspension force on the rotor (303) through interaction with the magnetic field emanating from the rotor (303). In the passive electromagnetic bearing mode, the driver (301) interconnects the pair of windings (304, 305) of the stator with each other so that the increase in magnitude of the magnetic flux in the one winding and the decrease in magnitude in the other winding of the pair of windings (304, 305) generates a suspension current in the pair of windings (304, 305). The suspension current causes the magnetic field produced by the stator to have a component that exerts a restoring force on the rotor (303) counteracting the displacement.
The present invention relates to a computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject, said method comprising the steps of: receiving (11) at least one image of the subject (20) and at least one clinical and/or biological data (21), both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image (12) based on at least one radiomic feature obtained for a region of interest (ROI) comprising at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject (13); determining (14) a risk (30) for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data (21).
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
45.
SYSTEM AND METHOD FOR DETERMINING A RISK OF HAVING OR DEVELOPING STEATOHEPATITIS AND/OR A COMPLICATION THEREOF
The present invention relates to a computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject, said method comprising the steps of: receiving (11) at least one image of the subject (20) and at least one clinical and/or biological data (21), both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image (12) based on at least one radiomic feature obtained for a region of interest (ROI) comprising at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject (13); determining (14) a risk (30) for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data (21).
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C. or lower at a breakable zone (210).
The present invention relates to the use of the expression levels of at least three biomarkers selected from the group consisting of SLC7A11, SERPINE1, PSAT1, PHGDH-1, TXNRD1, VIM, SNAI1, ZEB1, NANOG, SOX2, PCK2, G6PD, ASNS, NUPR1 and SLC6A9 as a molecular signature for identifying an individual with cancer, in particular breast cancer, as being susceptible to respond to a treatment by a mitochondria-targeted antioxidant.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
48.
MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS
The present invention relates to the use of the expression levels of at least three biomarkers selected from the group consisting of SLC7A11, SERPINE1, PSAT1, PHGDH-1, TXNRD1, VIM, SNAI1, ZEB1, NANOG, SOX2, PCK2, G6PD, ASNS, NUPR1 and SLC6A9 as a molecular signature for identifying an individual with cancer, in particular breast cancer, as being susceptible to respond to a treatment by a mitochondria-targeted antioxidant.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
In a modulated metasurface antenna, a surface wave transducer generates a surface wave when a radio-frequency excitation signal is applied to the surface wave transducer. The surface wave propagates throughout a surface wave propagation medium from the surface wave transducer to a rim of the surface wave propagation medium. The surface wave propagation medium has an electromagnetic surface impedance distribution (1000) that exhibits impedance variations that extend from the surface wave transducer to the rim of the surface wave propagation medium. The electromagnetic surface impedance distribution is non-uniform in azimuth direction on the surface wave propagation medium. Accordingly, there are azimuth ranges in which the impedance variations are smallest from the surface wave transducer to the rim of the surface wave propagation medium. The surface wave transducer has a non-uniform azimuthal surface wave power distribution so that, compared to a uniform azimuthal surface wave power distribution, a smaller amount of surface wave power is launched in the azimuth ranges (1001, 1002) where the impedance variations are the smallest. Accordingly, a significant proportion of the surface wave may leak from the surface wave propagation medium to produce radiation. This may significantly increase efficiency of the modulated metasurface antenna compared with prior art techniques.
H01Q 3/26 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la phase relative ou l’amplitude relative et l’énergie d’excitation entre plusieurs éléments rayonnants actifsDispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante
H01Q 13/28 - Antennes constituées par un guide non résonnant à ondes de fuite ou une ligne de transmissionStructures équivalentes produisant un rayonnement le long du trajet de l'onde guidée comportant des éléments présentant des discontinuités électriques et espacées dans la direction de la propagation de l'onde, p. ex. élément diélectrique ou élément conducteur formant diélectrique artificiel
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p. ex. dispositifs quasi optiques
A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.
A vaccine for treating and/or preventing a brain tumor. More particularly, a modified vesicular stomatitis virus glycoprotein (VSV-G) including at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine including a nucleic acid sequence encoding a modified VSV-G may be combined to a tumor resection in order to ameliorate the prognostic of the individuals.
A radiofrequency transducer assembly includes an antenna structure of the birdcage type. This antenna structure has longitudinally extending segments, which are arranged in a cylindrical configuration around a center axis, and at least one transversally oriented circular electrical coupling between the longitudinally extending segments. An electrically conductive shield surrounds the antenna structure of the birdcage type. The radiofrequency transducer assembly comprises a pair of electrically conductive bridges between a longitudinally extending segment of the antenna structure and the electrically conductive shield, which thereby jointly form an inductive loop.
G01V 3/00 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation
G01R 33/34 - Détails de structure, p. ex. résonateurs
53.
MANUFACTURING PROCESS FOR MULTI-PIXEL GAS MICROSENSORS WITH MULTIPLE SENSING CAPABILITIES
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
A polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits, and compositions and kits including the polypeptides.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
Provided is an instrument (100) for gauging a free margin (420) length (FML) of a heart valve cusp (410) in a vessel (416) comprising a gauging head (200) having a proximal (20) and distal end (40) comprising a body (210) having a prising member (212) at the distal (40) end adapted to be received within a cusp pocket (428) of the heart valve cusp and which extends in a proximal (20) direction to form a gauging member (220) of a fixed and defined length (L) adapted to abut the free margin (420), wherein the gauging member (220) comprises at either end a contact probe (222-a, 222-b) spaced apart by the fixed and defined length (L) and adapted to abut a vessel wall where the free margin edges attach.
The present invention relates to a polypeptide comprising the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. The invention also relates to the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The present invention relates to a polypeptide comprising the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. The invention also relates to the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
58.
CUTANEOUS DEVICE FOR STORING AND RELEASING MOLECULES, AND CORRESPONDING METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
YNCREA HAUTS DE FRANCE (France)
UNIVERSITE POLYTECHNIQUE DES HAUTS DE FRANCE (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgique)
Inventeur(s)
Szunerits, Sabine
Boukherroub, Rabah
Melinte, Sorin
Abrégé
The present invention relates to a cutaneous device (2) for the storage and release of molecules, in particular therapeutic molecules, comprising: —a support (6), —a matrix (8) configured to store and release the molecules as a function of the temperature, and —an electro-resistive layer, disposed between the support and the matrix, intended to be subjected to a voltage and comprising at least one thin microporous and/or nanoporous metal layer. The present invention also relates to a transcutaneous delivery device and the corresponding methods of manufacture and use.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
The present invention relates to a continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream comprising an absorption step of the carbon dioxide from a gas stream into an aqueous solution comprising a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. The invention also relates to a system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream comprising a control unit 10, an absorption unit 20 and a crystallization unit 30.
The present invention relates to a continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream comprising an absorption step of the carbon dioxide from a gas stream into an aqueous solution comprising a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. The invention also relates to a system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream comprising a control unit 10, an absorption unit 20 and a crystallization unit 30.
C01D 7/10 - Préparation de bicarbonates à partir de carbonates
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
B01D 63/00 - Appareils en général pour les procédés de séparation utilisant des membranes semi-perméables
61.
LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION
The present invention relates to lactam or lactone derivatives of formula la: or a pharmaceutically acceptable salt or solvate thereof, wherein X1is NH or O; X222, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z122, O, CR3or NR4; and R1, R2, R3and R4 each independently are H, alkyl or aryl;; and their use in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV- 2.
A61K 31/45 - Pipéridines non condensées, p. ex. pipérocaïne ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cycloheximide
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
62.
METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS
LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (Luxembourg)
Université catholique de Louvain (Belgique)
Inventeur(s)
Andre, Christelle
Leclercq, Joelle
Beaufay, Claire
Catteau, Lucy
Legay, Sylvain
Abrégé
The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composition comprising at least 3-O-p-coumaroyl ester of tormentic acid for a use in the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes, and to 3-O-p-coumaroyl ester of tormentic acid for its use as an antiparasitic agent for the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes.
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
C12P 15/00 - Préparation de composés contenant au moins trois carbocycles condensés
63.
PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION
A parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml, for use in a curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.
A61K 38/54 - Mélanges d'enzymes ou de proenzymes couverts par plus d'un seul des groupes ou
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61L 12/08 - Procédés ou appareils pour la désinfection ou la stérilisation des lentilles de contactAccessoires à cet effet utilisant des substances chimiques
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following two operations in an iterative manner. Measurements carried out by the follower aircraft are estimated (311) based on a simulated response of the follower aircraft to an estimated aerodynamic context (309). The estimated aerodynamic context (309) includes, on the one hand, a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and, on the other hand, data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context (309) is adjusted (308) based on a comparison between the measurements that have been estimated (311) and actual measurements (312) carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information (313) on the wake is extracted from the estimated aerodynamic context (309).
B64D 45/00 - Indicateurs ou dispositifs de protection d'aéronefs, non prévus ailleurs
G01C 23/00 - Instruments combinés indiquant plus d’une valeur de navigation, p. ex. pour l’aviationDispositifs de mesure combinés pour mesurer plusieurs variables du mouvement, p. ex. la distance, la vitesse ou l’accélération
G05D 1/10 - Commande de la position ou du cap dans les trois dimensions simultanément
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following two operations in an iterative manner. Measurements carried out by the follower aircraft are estimated (311) based on a simulated response of the follower aircraft to an estimated aerodynamic context (309). The estimated aerodynamic context (309) includes, on the one hand, a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and, on the other hand, data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context (309) is adjusted (308) based on a comparison between the measurements that have been estimated (311) and actual measurements (312) carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information (313) on the wake is extracted from the estimated aerodynamic context (309).
G05D 1/10 - Commande de la position ou du cap dans les trois dimensions simultanément
G01C 23/00 - Instruments combinés indiquant plus d’une valeur de navigation, p. ex. pour l’aviationDispositifs de mesure combinés pour mesurer plusieurs variables du mouvement, p. ex. la distance, la vitesse ou l’accélération
A strain sensor (100) is based on a self-biasing reference circuit that reaches an operating state that, at least at first order, is at least supply-voltage independent. The strain sensor (100) provides an output signal (201, 202) that is defined by the operating state of the self-biasing reference circuit. At least one component (107, 108) in the self-biasing reference circuit has an electrical characteristic that depends on a strain to which the at least one component (107, 108) is subjected. This makes that the operating state of the self-biasing reference circuit depends on the strain. As a result, the output signal (201, 202) of the strain sensor varies as a function of the strain to which the at least one component (107, 108) is subjected.
G01L 1/22 - Mesure des forces ou des contraintes, en général en mesurant les variations de la résistance ohmique des matériaux solides ou des fluides conducteurs de l'électricitéMesure des forces ou des contraintes, en général en faisant usage des cellules électrocinétiques, c.-à-d. des cellules contenant un liquide, dans lesquelles un potentiel électrique est produit ou modifié par l'application d'une contrainte en utilisant des jauges de contrainte à résistance
G01D 5/16 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension en faisant varier la résistance
G01D 3/036 - Dispositions pour la mesure prévues pour les objets particuliers indiqués dans les sous-groupes du présent groupe pour atténuer les influences indésirables, p. ex. température, pression sur les dispositions de mesure elles-mêmes
H03F 1/30 - Modifications des amplificateurs pour réduire l'influence des variations de la température ou de la tension d'alimentation
G01B 7/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p. ex. au moyen d'une jauge de contrainte à résistance
G01D 3/02 - Dispositions pour la mesure prévues pour les objets particuliers indiqués dans les sous-groupes du présent groupe avec dispositions pour changer ou corriger la fonction de transfert
H03F 3/347 - Amplificateurs de courant continu dans lesquels tous les étages sont couplés en courant continu comportant uniquement des dispositifs à semi-conducteurs dans des circuits intégrés
The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
In an energy harvesting system (400), a power extraction circuit (404) extracts electrical power from an environmental power source susceptible of providing a level of power that fluctuates. An electrical power storage device (406) stores the electrical power extracted from the environmental power source by the power extraction circuit (404). A sensing circuit (407) provides an indication (409) of a level of power that the power extraction circuit (404) can extract from the environmental power source. A controlled switch circuit (408) electrically decouples the power extraction circuit (404) from the electrical power storage device (406) when the indication (409) indicates that the level of power that the power extraction circuit (404) can extract from the environmental power source is insufficient for the power extraction circuit (404) to charge the electrical power storage device (406). This prevents leakage of harvested power.
Guanabenz for use with an immunotherapy in the treatment of a cancer or of an infectious disease. In particular, guanabenz is used as an adjuvant for an immunotherapy, such as a cancer immunotherapy or a vaccination. More specifically, guanabenz for use with an adoptive cell therapy, with a therapeutic vaccine, with a checkpoint inhibitor therapy or with a T-cell agonist therapy in the treatment of a cancer. Also, guanabenz for use with a vaccination in the prophylactic and/or therapeutic treatment of an infectious disease.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
73.
ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha- 2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
A prosthesis or orthosis for a joint, such as an ankle, which includes a first body, a second body, and an articulated joint between the first and second bodies, the articulated joint allowing the rotation of the first and second bodies with respect to one another around a joint rotation axis. It further includes a locking mechanism configured to selectively lock the rotation between the first and second bodies in one direction, when it is in a locked configuration, and a transmission mechanism such that a rotation of the joint rotation axis generates a movement of a lockable part of the locking mechanism. The axis of the movement of the lockable part is shifted relative to the joint rotation axis and the transmission mechanism includes a reducer configured to reduce effort to lock the rotation of the first body with respect to the second body.
A61F 2/70 - Moyens d'actionnement ou de commande électriques
A61F 5/01 - Dispositifs orthopédiques, p. ex. dispositifs pour immobiliser ou pour exercer des pressions de façon durable pour le traitement des os fracturés ou déformés, tels que éclisses, plâtres orthopédiques ou attelles
A61F 2/50 - Prothèses non implantables dans le corps
An example device includes a processor configured to receive a plurality of voltage values representing respective voltage magnitudes at voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02J 3/32 - Dispositions pour l'équilibrage de charge dans un réseau par emmagasinage d'énergie utilisant des batteries avec moyens de conversion
H02J 3/46 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs contrôlant la répartition de puissance entre les générateurs, convertisseurs ou transformateurs
G05B 19/042 - Commande à programme autre que la commande numérique, c.-à-d. dans des automatismes à séquence ou dans des automates à logique utilisant des processeurs numériques
H02J 3/00 - Circuits pour réseaux principaux ou de distribution, à courant alternatif
79.
Plants with modified lipid metabolism and methods for making the same
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Batoko, Henri
Moreau, Patrick
Abrégé
The present invention relates generally to the field of plant molecular biology and relates to plants having a modified lipid metabolism and to methods for making such modified plants. In particular, the invention provides modified plants and parts thereof, including seeds, having an increased level of triacylglycerol (TAG), by means of a seed-specific expression in seed tissues during seed filling of a nucleic acid encoding a translocator protein (TSPO) in said modified plants or parts thereof. The invention further relates to methods for modulating lipid metabolism in plants and for producing plants with a modified lipid metabolism. The invention also provides constructs, vectors and host cells useful in the methods of the invention, and further relates to products obtained from the modified plants.
A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C or lower at a breakable zone (210).
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
A61B 5/154 - Dispositifs de prélèvement d'échantillons de sang spécialement adaptés pour le prélèvement d'échantillons de sang veineux ou artériel, p. ex. par des seringues utilisant des moyens préalablement mis sous vide
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
81.
Integrated circuit device and method of manufacturing thereof
An integrated circuit device includes a semiconductor substrate having a resistivity of at least 100 Ω·cm. An electrically insulating layer contacts the semiconductor substrate. The electrically insulating layer is susceptible of inducing in the semiconductor substrate a parasitic surface conduction layer that interfaces with the electrically insulating layer. An electrical circuit is located on the electrically insulating layer. The electrical circuit includes a section capable of inducing an electrical field in the semiconductor substrate. The integrated circuit device includes a depletion-inducing junction of which at least a portion is comprised in the semiconductor substrate. The depletion-inducing junction can autonomously induce in the semiconductor substrate a depleted zone that interfaces with a section of the electrically insulating layer that lies in-between two sections of the electrical circuit.
H01L 21/84 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun avec une division ultérieure du substrat en plusieurs dispositifs individuels pour produire des dispositifs, p.ex. des circuits intégrés, consistant chacun en une pluralité de composants le substrat étant autre chose qu'un corps semi-conducteur, p.ex. étant un corps isolant
H01L 27/12 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant autre qu'un corps semi-conducteur, p.ex. un corps isolant
H01L 49/02 - Dispositifs à film mince ou à film épais
A radiofrequency transducer assembly (104) comprises an antenna structure of the birdcage type. This antenna structure has longitudinally extending segments (201), which are arranged in a cylindrical configuration around a center axis, and at least one transversally oriented circular electrical coupling (205) between the longitudinally extending segments. An electrically conductive shield (107) surrounds the antenna structure of the birdcage type. The radiofrequency transducer assembly (104) comprises a pair of electrically conductive bridges (307, 308) between a longitudinally extending segment (201) of the antenna structure and the electrically conductive shield (107), which thereby jointly form an inductive loop (302).
The present invention relates to processes for producing, isolating and recovering various useful components from solid lignocellulosic biomass. More in particular, the invention provides a process for producing lignin components comprising lignin monomers, lignin dimers and lignin oligomers, from lignocellulosic biomass, wherein said lignocellulosic biomass comprises cellulose, hemicellulose and lignin, said process comprising the steps of: a) providing said lignocellulosic biomass as a solid biomass, b) contacting said lignocellulosic biomass with a composition comprising a sulphur containing reducing agent, and an organic solvent, optionally provided in a mixture with water, and obtaining lignin components comprising lignin monomers, lignin dimers and lignin oligomers, and c) isolating and recovering said lignin components. The lignocellulosic biomass provided in step a) is not chemically treated prior to contacting with said composition in step b) but is applied as raw biomass. The present invention also relates to components produced from the lignocellulosic biomass in accordance with disclosed processes and to uses thereof in various applications.
The present invention relates to a vaccine for treating and/or preventing a brain tumor. More particularly, the invention relates to a modified vesicular stomatitis virus glycoprotein (VSV-G) comprising at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine comprising a nucleic acid sequence encoding a modified VSV-G according to the invention may be combined to a tumor resection in order to ameliorate the prognostic of said individuals.
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
87.
Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
88.
USE OF PASTEURIZED AKKERMANSIA FOR TREATING METABOLIC DISORDERS
The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61Q 19/06 - Préparations pour lutter contre la cellulite
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A substrate has a front side including an electrical circuit and a rear side including an exposed zone that faces the electrical circuit. In an electrochemical treatment step, an electrical potential is laterally applied at least to the exposed zone of the rear side of the substrate, while the exposed zone is in contact with a chemically reactive substance. The electrical potential causes a lateral flow of electrical current at least in the exposed zone of the substrate. The lateral flow of current and the chemically reactive substance alter the substrate in at least the exposed zone.
The present invention relates to a lipid nanocapsule for oral administration comprising a solid lipid outer shell and a lipophilic liquid inner core comprising reverse micelles loaded with one or more incretin mimetics. The present invention also relates to the use of lipid nanocapsules for treating and/or preventing a disorder associated with a GLP-1 dysfunction.
G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projetsPlanification d’entreprise ou d’organisationModélisation d’entreprise ou d’organisation
p, the turns of the first subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, the turns of the second subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, a turn of the first subgroup being connected to a turn of the second subgroup in such a way that the direction of said current in the first group is opposite to the direction of the current in the second subgroup. The winding is a wave winding comprising vertical shortcut connections.
H02K 3/28 - Schémas d'enroulements ou de connexions entre enroulements
H02K 3/26 - Enroulements caractérisés par la configuration, la forme ou le genre de construction du conducteur, p. ex. avec des conducteurs en barre constitués par des conducteurs imprimés
The present invention relates to a polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, the invention relates to linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
94.
LACTATE DEHYDROGENASE INHIBITOR POLYPEPTIDES FOR USE IN THE TREATMENT OF CANCER
The present invention relates to a polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, the invention relates to linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
C12Q 1/32 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase une déshydrogénase
95.
CUTANEOUS DEVICE FOR STORING AND RELEASING MOLECULES, AND CORRESPONDING METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
YNCREA HAUTS DE FRANCE (France)
UNIVERSITE POLYTECHNIQUE DES HAUTS DE FRANCE (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgique)
Inventeur(s)
Szunerits, Sabine
Boukherroub, Rabab
Melinte, Sorin
Abrégé
The present invention relates to a cutaneous device (2) for the storage and release of molecules, in particular therapeutic molecules, comprising: - a support (6), - a matrix (8) configured to store and release the molecules as a function of the temperature, and - an electro-resistive layer, disposed between the support and the matrix, intended to be subjected to a voltage and comprising at least one thin microporous and / or nanoporous metal layer. The present invention also relates to a transcutaneous delivery device and the corresponding methods of manufacture and use.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
p, the turns of the first subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, the turns of the second subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, a turn of the first subgroup being connected to a turn of the second subgroup in such a way that the direction of said current in the first group is opposite to the direction of the current in the second subgroup.
H02K 3/28 - Schémas d'enroulements ou de connexions entre enroulements
H02K 3/26 - Enroulements caractérisés par la configuration, la forme ou le genre de construction du conducteur, p. ex. avec des conducteurs en barre constitués par des conducteurs imprimés
LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LIST) (Luxembourg)
UNIVERSITÉ CATHOLIQUE DE LOUVAIN (Belgique)
Inventeur(s)
Leclercq, Joëlle
Beaufay, Claire
Catteau, Lucy
Andre, Christelle
Legay, Sylvain
Abrégé
O-pO-pO-pO-p-coumaroyl ester of tormentic acid for its use as an antiparasitic agent for the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes.
Aspects of the invention concern a composition or a kit-of-parts comprising i) a virus which is a member of the Reoviridae family and ii) sialic acid and/or a molecule comprising at least one sialic acid moiety, as well therapeutic applications thereof.
A61K 31/7012 - Composés ayant un groupe carboxyle libre ou estérifié, lié directement ou par une chaîne carbonée, à un atome de carbone du radical saccharide, p. ex. acide glucuronique, acide neuraminique
Aspects of the invention concern a composition or a kit-of-parts comprising i) a virus which is a member of the Reoviridae family and ii) sialic acid and/or a molecule comprising at least one sialic acid moiety, as well therapeutic applications thereof.
A61K 31/7012 - Composés ayant un groupe carboxyle libre ou estérifié, lié directement ou par une chaîne carbonée, à un atome de carbone du radical saccharide, p. ex. acide glucuronique, acide neuraminique
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
